gad-alum
Vaccineexperimental
Glutamate decarboxylase or glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the decarboxylation of glutamate to gamma-aminobutyric acid (GABA) and carbon dioxide. GAD uses pyridoxal-phosphate (PLP) as a cofactor. The reaction proceeds as follows:HOOC−CH2−CH2−CH(NH2)−COOH → CO2 + HOOC−CH2−CH2−CH2NH2 — Wikipedia
Clinical trial activity
5 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00529399)
Timeline
Indications
Studied for
- Autoimmune Diseases · Phase 2
- Diabetes Mellitus · Phase 2
- Diabetes Mellitus, Type 1 · Phase 2
- Endocrine System Diseases · Phase 2
- Glucose Metabolism Disorders · Phase 2
- Immune System Diseases · Phase 2
- Latent Autoimmune Diabetes in Adults · Phase 2
- Metabolic Diseases · Phase 2
- Physiological Effects of Drugs · Phase 2
- Vitamin D · Phase 2
Mechanism of action
- Glutamate dehydrogenaseImmunity, active
GLUD1 immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGlutamate decarboxylase ↗
- NCATSI7YY5T4995 ↗
- ChEMBLCHEMBL4594599 ↗
Also known as
- gad-alum
- glutamic acid decarboxylase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05351879 | Phase 1/Phase 2 (Phase 2) | May 9, 2022 | Diamyd, Linkoping University |
| NCT04262479 | Phase 2 | Feb 29, 2020 | Diamyd, Karolinska Institute, Linkoping University, Norwegian University of Science and Technology |
| NCT03345004 | Phase 2 | Dec 20, 2017 | Diamyd, Linkoping University |
| NCT02002130 | Phase 1 | Jan 1, 2015 | Diamyd, Janssen Pharmaceutica NV, Juvenile Diabetes Research Foundation, NOW Foods, University of Alabama, Birmingham |
| NCT00529399 | Phase 2 | Feb 1, 2009 | American Diabetes Association, Juvenile Diabetes Research Foundation, National Center for Research Resources (NCRR), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), University of Miami, University of Toronto |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Diamyd | For profit | 4 | 1 | 2 | 2015 |
| Linkoping University | Academic/Hospital | 3 | 1 | 1 | 2017 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 2 | 0 | 2 | 2009 |
| American Diabetes Association | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2015 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| National Center for Research Resources (NCRR) | Government | 1 | 0 | 1 | 2009 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2009 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2009 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2009 |
| Norwegian University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| NOW Foods | For profit | 1 | 0 | 1 | 2015 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Miami | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2009 |
15 organizations
Page 1 / 1